# Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Source: https://onco.cc/trials/nct06840119/  
OnCo record `nct06840119` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IMC-R117C in advanced solid tumours, run by Immunocore Ltd, now recruiting.

## Summary

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers is a phase 1/2 interventional study registered as NCT06840119 by Immunocore Ltd, with 600 participants planned, started 2024-01-10 and due to reach its primary completion in 2026-11-30. Interventions recorded: IMC-R117C, Chemotherapy drug, Kinase inhibitor, Antiangiogenic Agent and Monoclonal antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06840119
- Phase: 1/2
- Setting: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers
- Sponsor: Immunocore Ltd
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT06840119: https://clinicaltrials.gov/study/NCT06840119

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Immunocore](https://onco.cc/companies/immunocore/)

---
JSON: https://onco.cc/api/v1/entities/nct06840119.json